The beat drives near-term bullish momentum, but the guidance cut due to the Emalex acquisition introduces uncertainty. Watch for details on Emalex integration and biosimilar approvals (PONLIMSI, Xolair biosimilar) over the next few quarters.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $35.39entry
- T+1 · 7mo ago −0.87%α −1.90% · $35.08
- T+5 · 7mo ago +2.37%α −0.74% · $36.23
- T+20 · 6mo ago −2.71%α −8.76% · $34.43
- T+60 · 4mo ago −11.89%α −15.62% · $31.18
Price Chart
How similar events traded
Executive Summary
Teva reported Q1 2026 non-GAAP EPS of $0.53, beating consensus of $0.46 by 15%, and revenue of $3.98B, beating $3.79B by 5%. Innovative products (AUSTEDO, AJOVY, UZEDY) grew 41% YoY, offsetting generic erosion. However, 2026 guidance was effectively lowered from prior stand-alone due to the Emalex acquisition, with non-GAAP diluted EPS now guided at $1.91-$2.11 vs. prior $2.57-$2.77.
Key Financial Metrics
Key Facts
- Non-GAAP diluted EPS $0.53 vs. consensus $0.46 (beat 15.2%)
- Revenue $3.98B vs. consensus $3.79B (beat 5.1%)
- Revenue growth +2% USD (-3% local currency); YoY revenue up $91M
- Innovative brands (AUSTEDO, AJOVY, UZEDY) grew 41% YoY in local currency
- Generics revenue down 16% in local currency, driven by lenalidomide competition
- 2026 guidance maintained but lowered from stand-alone: non-GAAP EPS $1.91-$2.11 (stand-alone $2.57-$2.77) due to Emalex acquisition
- Board authorized future share repurchase program (not yet implemented)
- Free cash flow of $188M; operating cash flow negative $40M due to working capital
Financial Impact
Earnings beat of $0.07/share vs consensus; revenue beat of ~$192M; guidance cut of ~$0.66/share from prior stand-alone
Risk Factors
- Accelerating generic competition for lenalidomide capsules
- Execution risk on Emalex integration and pipeline milestones
- High debt ($16.6B) and financial leverage (67%)
- Foreign exchange volatility (positive impact in Q1 but uncertain going forward)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283605 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers